NCT02594384View on ClinicalTrials.gov

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

March 9, 2020

Study Completion Date

March 30, 2023

Conditions
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
Interventions
DRUG

LAM-002A

25 mg capsules or 50 mg capsules

DRUG

Rituximab

375 mg/m2 by vein

DRUG

Atezolizumab

1200 mg by vein

Trial Locations (11)

10016

New York University School of Medicine, New York

10021

Weill Cornell Medical College, New York

22031

Virginia Cancer Specialists, Fairfax

30322

Winship Cancer Institute at Emory University, Atlanta

32224

Mayo Clinic, Jacksonville

35805

Clearview Cancer Institute, Huntsville

47905

Horizon Oncology Research, Inc., Lafayette

55905

Mayo Clinic, Rochester

77030

University of Texas MD Anderson Cancer Center, Houston

98101

Virginia Mason Medical Center, Seattle

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

OrphAI Therapeutics

INDUSTRY

NCT02594384 - A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter